Interim Analysis of Phase III REGENERATE: Obeticholic Acid vs Placebo for NASH

April 10-14, 2019; Vienna, Austria
Obeticholic acid showed significant, dose-dependent improvement in the primary endpoint of fibrosis improvement with no worsening of NASH in this interim analysis of a large randomized trial.
Format: Microsoft PowerPoint (.ppt)
File Size: 195 KB
Released: April 16, 2019

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grant provided by:
AbbVie
Gilead Sciences

Related Content

Expert insight on the burden and impact of HBV infection, as well as strategies to overcome barriers to vaccination, from Clinical Care Options (CCO)

Robert G. Gish, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: March 22, 2022 Expired: March 21, 2023

CCO faculty Manal F. Abdelmalek, MD, MPH, answers FAQs in NASH management including how to incorporate noninvasive biomarkers and treatment options

Manal F. Abdelmalek, MD, MPH Released: January 16, 2020

Watch this video from a live symposium for expert guidance on approaches to improve diagnosis and treatment of HCV, HBV, and NASH.

Paul Y. Kwo, MD
Program Director
Manal F. Abdelmalek, MD, MPH Oluwaseun Falade-Nwulia, MBBS, MPH
Physicians: maximum of 1.5 AMA PRA Category 1 Credits US Physicians: maximum of 1.5 Medical Knowledge MOC point(s) Released: December 17, 2019 Expired: No longer available for credit

Downloadable slides on data from AALSD 2019 selected by expert faculty as relevant to care of patients with viral hepatitis or NAFLD/NASH, as reported by Clinical Care Options.

Ira M. Jacobson, MD Nancy Reau, MD Released: December 2, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings